Oral BG-12 Drops Relapses by Half

BG-12, an experimental oral medication, reduced relapses by 53% in the global clinical trial called DEFINE.  The medication also had a positive impact on slowing the progression of disability by 38%.  The DEFINE study involved more then 1200 relapsing remitting patients.  Full trial results have not been released.   In the Phase II clinical trial, side effects were nausea, flushing and elevated liver enzymes.  A separate Phase III trial is ongoing with a group of patients also on Copaxone as a comparison treatment.